Another GU FDA approval June 12, 2026:
Capivasertib + Abi/Pred in mCSPC, based on ➕rPFS (HR 0.81)
⚠️ OS immature
⚠️ cost/toxicity: diarrhea, ⬆️BG, rash
❓How does it compare to triplet w/ docetaxel
❓biomarker refinement: IHC cutoff 90% vs NGS PTEN-loss VS p-AKT
❓duration
Cracked ctDNA in #kidneycancer, showed relative contribution with KIM-1 *and* harnessed prognostic information to guide patient care in oligometastatic disease via K-COMPASS 👉 https://t.co/DnlfqzoXVJ 🔬
Not many prostate bispecifics in the oral sessions at ASCO this year. Most of the activity was in the posters.
Four programs, four targets:
🔬 STEAP1 × CD3, xaluritamig + abiraterone (Sumey, 5070): the only one with efficacy data. PSA50 65%, RECIST ORR 57% in taxane-naïve mCRPC. Inphase 3 XALience.
🔬 KLK2 × CD3, pasritamig + docetaxel (PASenger, TPS5139): already in randomized phase 3, n=800, rPFS primary.
🔬 DLL3 × CD3, tarlatamab (TIDAL, TPS5142): phase 2 in DLL3-positive neuroendocrine prostate, a setting with few options.
🔬 VEGF × PD-1, ivonescimab (NCT06567314): not a T-cell engager, testing the microenvironment in mCRPC.
The targets are diversifying (STEAP1, KLK2, and DLL3 each handle prostate specificity differently), and the trials are moving earlier rather than sitting late salvage.
Excited to follow this movement and the idea of an immune based therapy in this typically immune resistant tumor.
#ProstateCA #mCRPC #GUonc #ASCO26 @OncoAlert
MEVPRO-3 trial: Enzalutamide with or without mevrometostat in metastatic hormone-sensitive #ProstateCancer. @neerajaiims@huntsmancancer joins @l_ballas@CedarsSinai to discuss the MEVPRO-3 trial design which enrolls 1,000 patients with newly diagnosed #mHSPC randomized to ADT + enzalutamide vs ADT + enzalutamide + mevrometostat. #WatchNow > https://t.co/9rvt7FPUpN
#ASCO26 Panitumumab showed remarkable activity in SMARCB1-deficient renal medullary carcinoma, achieving an ORR of 54% with 15% CR in heavily pretreated patients. These data support wild-type EGFR as a promising therapeutic target in one of the most aggressive kidney cancers
Darolutamide alone for nonmetastatic #CSPC: 52-week safety and efficacy results from the #ARAMON trial. @alaccetti@nyulangone joins @TDorffOnc@cityofhope to discuss the 52-week results from ARAMON, a phase 2 study of darolutamide monotherapy in biochemically recurrent and low-volume metastatic prostate cancer. #WatchNow > https://t.co/ZrUKkNV2s5
Congrats to Dr Taplin, all @DanaFarber_GU@DanaFarber and #PROTEUS team on a new frontier in high-risk prostate cancer.
Now officially in @NEJM !
https://t.co/36dUY9OUBN
Ab#4515 @ASCO#ASCO26 by @emanuele_crupi👉 https://t.co/nAA0Rgbb30👉Ph2 study of gemcitabine, 5-FU, and cisplatin (GemFLP) in advanced urinary tract adenoCa#bladdercancer👉44% ORR w/ durable response & baseline CA125 was associated w/ OS👇@OncoAlert@urotoday@bladdercancerUS
What started as a concept to enhance advanced training MedEd is now presented at #ASCO26🎉. Catch our poster on 6/1. Excited for learning and reconnecting with friends and mentors. #MedEd need of the hour @OSUhemoncfellow@RushHemOnc@Sonia_lite https://t.co/9Ogou9UHnJ
First in class PD1/CTLA4 bispecific ph1 in nccRCC #ASCO26
➡️37 pts, ORR 51.6% esp in liver mets, mPFS 16.7 mo
⛔️ heterogeneity & high FH def population, no DLTs
✅promising 1L and manageable safety, not ready for clinic, but reinforces IO/TKI in nccRCC, driven by FH-def
One to watch at #ASCO26: TALAPRO-3, a Late-Breaking Oral Abstract evaluating talazoparib + enzalutamide in HRR-altered metastatic castration-sensitive prostate cancer @neerajaiims@ASCO
https://t.co/ByNa4SiPOU
Honored to be part of this @sitcancer guideline on IO for #KidneyCancer
This work offers evidence- & consensus-based recommendations for adjuvant & metastatic RCC, special populations, response monitoring, & patient education/QOL @DrRanaMcKay@montypal
https://t.co/HkwhHm3Brm
Cabazitaxel shows consistent real-world effectiveness in mCRPC, regardless of line of therapy @JCOOA_ASCO@Micah_Ostrowski@neerajaiims@umangtalking
In 1,315 patients:
🔵rwTTNT: 4.7 months
🔵rwOS: 8.6 months
https://t.co/9z0TuvPrnD